Refolo, L M <br/><br/>
A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.  [electronic resource] 

 -  Neurobiology of disease  Oct 2001 
 - 890-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0969-9961 
<br/><br/><label>Standard No.: </label>10.1006/nbdi.2001.0422  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alzheimer Disease--blood<br/>Amyloid Precursor Protein Secretases<br/>Amyloid beta-Peptides--analysis<br/>Amyloid beta-Protein Precursor--analysis<br/>Animals<br/>Anticholesteremic Agents--pharmacology<br/>Aspartic Acid Endopeptidases<br/>Brain Chemistry--drug effects<br/>Cholesterol--analysis<br/>Disease Models, Animal<br/>Drug Evaluation, Preclinical<br/>Endopeptidases--metabolism<br/>Enzyme Inhibitors--pharmacology<br/>Female<br/>Humans<br/>Male<br/>Membrane Proteins--analysis<br/>Mice<br/>Mice, Transgenic<br/>Nerve Tissue Proteins--analysis<br/>Oxidoreductases--antagonists & inhibitors<br/>Oxidoreductases Acting on CH-CH Group Donors<br/>Piperazines--pharmacology<br/>Presenilin-1<br/>Protein Processing, Post-Translational--drug effects<br/>Serum Amyloid P-Component--analysis